<DOC>
	<DOCNO>NCT01231620</DOCNO>
	<brief_summary>The purpose study test safety efficacy zanamivir give intravenously well work two different dos hospitalize adolescent adult flu . Zanamivir compare oseltamivir , use treat flu .</brief_summary>
	<brief_title>A Study Intravenous Zanamivir Versus Oral Oseltamivir Adults Adolescents Hospitalized With Influenza</brief_title>
	<detailed_description>The recent influenza pandemic highlight need alternative formulation anti-influenza therapy . This international Phase III , double-blind , double-dummy , 3-arm study evaluate efficacy , antiviral activity safety IV zanamivir 600 mg twice daily compare oral oseltamivir 75 mg twice daily , 600 mg IV zanamivir twice daily compare 300 mg IV zanamivir 5 day hospitalize subject laboratory confirm suspect influenza infection . For give subject , initial 5-day treatment course may extend 5 additional day clinical symptom patient characteristic assess investigator warrant treatment . Alternatively , investigator considers subject fail improve clinically randomize treatment , investigator choose initiate switch/rescue option ( 600 mg IV zanamivir twice daily ) day Day 6 Day 10 additional 5 day treatment . On switch treatment , subject complete maximum 14 day treatment followed-up Post-Treatment +28 Days .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Male female age 16 year ; female eligible enter participate study : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female post menopausal ) ; , 2. childbearing potential , negative pregnancy test Baseline , agree use protocol specify method birth control study . Vital sign criterion define 3 follow Baseline : 1 . Presence fever [ oral temperature 38°C equivalent ] Baseline . However , requirement waive subject history fever within 24 hour prior Baseline ; , subject report symptom feverishness time 48 hour prior Baseline . AND least 2 follow 4 : 2 . Oxygen saturation &lt; 95 % room air transcutaneous method need supplemental oxygenation ventilatory support , increase oxygen supplementation requirement ≥2 litres subject chronic oxygen dependency . For subject history chronic hypoxia ( without supplemental oxygen ) , oxygen saturation least 3 % patient 's historical baseline oxygen saturation satisfy criterion . 3 . Respiration rate &gt; 24 breath per minute . For subject require ventilatory support oxygen supplementation , requirement waive . 4 . Heart rate &gt; 100 beat per minute . 5 . Systolic blood pressure &lt; 90 mmHg . Onset influenza symptom within 6 day prior study enrolment . Symptoms may include cough , dyspnea , sore throat , feverishness , myalgia , headache , nasal symptom ( rhinorrhea , congestion ) , fatigue , diarrhea , anorexia , nausea vomiting . Clinical symptom influenza positive influenza diagnostic test result strong suspicion influenza illness base clinical symptom local surveillance information . Subjects willing able give write informed consent participate study adhere procedure state protocol , legally acceptable representative willing able give write informed consent behalf subject minor , unconscious adult incapable consent due medical condition , include permitted local regulatory authority , IRB/IECs local law . Severity medical illness , Investigator 's judgement , justifies hospitalization subject treatment supportive care French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category Subjects take total 3 day ( 6 dos ) approve antiinfluenza therapy period onset symptom prior enrolment . Subjects , opinion investigator , likely survive beyond 48 hour Baseline . Subjects consider require concurrent therapy another influenza antiviral medication . Subjects know suspected hypersensitive component study medication . Subjects creatinine clearance ≤10 mL/min treat continuous renal replacement therapy ( CRRT ) . Subjects require Extra Corporeal Membrane Oxygenation ( ECMO ) Baseline Subjects require routine/intermittent hemodialysis continuous peritoneal dialysis ( due inability provide appropriate dosing schedule oseltamivir ) Baseline . CRRT modality allow . Liver toxicity criterion base local laboratory result obtain within 24 hour Baseline : 1 . ALT AST 3xULN bilirubin 2xULN 2 . ALT 5xULN Underlying chronic liver disease evidence severe liver impairment . History severe cardiac disease clinically significant arrhythmia ( either ECG history ) , opinion Investigator , interfere safety individual subject . Females pregnant breastfeeding . Treatment investigational parenteral antiinfluenza drug ( IV peramivir , IV zanamivir IV oseltamivir ) 4 week prior Baseline . French Korean subject : French Korean subject participate study use investigational drug previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Seasonal Influenza</keyword>
	<keyword>Pandemic</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
	<keyword>Influenza</keyword>
	<keyword>Influenza A Virus , H1N1 Subtype</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Influenza , seasonal</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Zanamivir</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>H1N1</keyword>
	<keyword>Neuraminidase inhibitor</keyword>
	<keyword>Influenza B virus</keyword>
</DOC>